TOTAL VOLUME:

$154.4b

24H VOL:

$235,918,089

24H TRANSACTIONS:

2,984,028,936

OPEN INTEREST:

$1,884,820,873

413,109

Markets across

40,428

events

MATCHED EVENTS:

4,364

PLATFORM COVERAGE:

5

Polymarket:

37%

VS.

Kalshi:

63%

BETA
Dashboards
Insights
Indices
API
Tour
All
Trending
Breaking
New
Ending Soon
Politics
Sports
Elections
Crypto
Companies
Financials
Economics
Other
Entertainment
Science and Technology
Will AbbVie Q3 Global Rinvoq net revenues be above __?
polymarket

Will AbbVie Q3 Global Rinvoq net revenues be above?

Volume:
$3,852

$2.6B

 - Polymarket

$2.6B - Polymarket

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved Oct 30, 2026

Closed: Oct 30, 9:48 AM EST

polymarket

Polymarket

View
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
polymarket

$2.6B

View
100%
25%
Yes 100¢No 0¢
—
N/A
$1,374
N/A
N/A
N/A
Settled
Yes
polymarket

$2.7B

View
100%
29%
Yes 100¢No 0¢
—
N/A
$836
N/A
N/A
N/A
Settled
Yes
polymarket

$3.0B

View
0%
37%
Yes 0¢No 100¢
—
N/A
$624
N/A
N/A
N/A
Settled
No
polymarket

$2.8B

View
0%
47%
Yes 0¢No 100¢
—
N/A
$616
N/A
N/A
N/A
Settled
No
polymarket

$2.9B

View
0%
39%
Yes 0¢No 100¢
—
N/A
$401
N/A
N/A
N/A
Settled
No
Total markets: 5

Description

This market will resolve to "Yes" if AbbVie's Global Rinvoq net revenues for the upcoming third fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by November 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Polymarket

This market will resolve to "Yes" if AbbVie's Global Rinvoq net revenues for the upcoming third fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by November 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Frequently asked questions

On Polymarket, the dashboard for the AbbVie Rinvoq revenues market tracks the current odds of AbbVie’s Q3 global Rinvoq net revenues exceeding a specific threshold. You can view the implied probability of different outcomes, along with the 24-hour trading volume of $1,281 and the total volume traded to date of $3,751. The dashboard provides a historical price chart, allowing you to analyze how the market has priced this event over time. This provides a clear view of market sentiment regarding AbbVie’s performance.

Currently, the odds on Polymarket suggest a very high probability of AbbVie’s Q3 global Rinvoq net revenues being above the threshold. This differs from some analyst forecasts, which present a wider range of expectations. While some analysts align with the market’s bullish outlook, others predict a more conservative revenue figure. It’s important to note that prediction markets represent the collective wisdom of traders willing to put capital behind their beliefs, potentially offering a distinct perspective compared to traditional financial analysis. This market reflects what traders believe will happen, not necessarily what analysts predict.

On Polymarket, this market is priced through a continuous auction mechanism where traders buy and sell shares representing their belief about whether AbbVie’s Q3 global Rinvoq net revenues will be above the specified amount. The price of these shares fluctuates based on supply and demand, directly reflecting the collective probability assigned to the outcome. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The price movement is influenced by new information, market sentiment, and trading activity. Higher demand for shares indicating a ‘yes’ outcome pushes the price up, and vice versa.

This market resolves around Oct 30, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. Specifically, the official Q3 global Rinvoq net revenues reported by AbbVie will be compared to the threshold specified in the market question. The resolution will be based on the official figures released by AbbVie and verified against credible public sources. Traders will then be paid out based on whether their prediction aligned with the actual reported revenues.

Several signals could significantly impact this market. Any news regarding clinical trial results for Rinvoq, updates on regulatory approvals in key markets, or changes in the competitive landscape for similar drugs could all move the market. Furthermore, AbbVie’s overall financial performance and any revisions to their revenue guidance would be closely watched. Unexpected macroeconomic factors impacting the pharmaceutical industry or healthcare spending could also play a role. Positive or negative developments in these areas could shift trader sentiment and alter the odds in this market.